I-FIGS Feasibility Study
NCT05616039 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42
Last updated 2025-08-01
Summary
Background:
Removal of part of the liver (resection) is performed as a treatment for some cancers in the liver. To achieve the best possible outcomes, it is important that the cancer is removed completely (R0 resection) (1). Up to 30-50% patients develop recurrence within 2 years of surgery which could be due to incomplete removal of the cancer (2). Various techniques are used by the surgeons to identify the cancer tissue from the normal liver during the surgery so that it can be removed completely. These include examining with the naked eye, having a feel of the tumour, and performing an ultrasound scan. Even with these techniques it is difficult to identify the exact extent of the cancer. Also, the interpretation of the ultrasound scan can be subjective (3). A robust, objective, real-time navigation technique is required which can differentiate cancer from normal tissue.
Indocyanine green (ICG) is a dye which when given through the veins, is taken up and retained by cancer cells in the liver and they appear as fluorescent areas as compared to normal liver which appears dark. This principle can be used to identify the cancerous tissue accurately during the surgery and remove it completely (Indocyanine green Fluorescence Image-Guided Surgery: I-FIGS). It can also potentially detect additional tumours which were not identified before the surgery or during the surgery with standard techniques (4,5). However, there is a lack of good quality evidence on the usefulness of I-FIGS in liver surgery, so this needs to be tested in a large group of patients having liver surgery before any recommendations can be made.
Research Aim:
This initial study aims to assess whether a larger trial evaluating the role of I-FIGS in complete removal of the cancer tissue is feasible. Investigators will assess if patients are willing to take part in the study and whether they can gather relevant clinical outcome data from them all. Investigators will also gather patients' views about this novel technique and participating in the study.
Design and methods:
This study will involve 40 patients having planned liver surgery for liver tumour/s recruited from University Hospitals, Plymouth. Patients will be randomly allocated to have I-FIGS plus standard surgery or standard liver surgery alone. Patients in the I-FIGS group will have ICG injection 2-4 hrs prior to surgery (0.03-0.05mg/kg dose) on the day of surgery. The surgical planning will be carried out as per the standard approach using the naked eye and intra-operative ultrasound examination. Once this is all recorded, ICG cameras will be switched on, and the additional findings and change to surgical plan will be noted. Focus groups will explore participants experiences of being in the study. This will inform the design of the future larger trial.
Patient public involvement:
Investigators have involved patients who have had or are having liver surgery in the development of the study. Their views on the technique, trial procedures and outcome measures have been incorporated. They will continue to be involved and advise on the study.
Dissemination:
Results will be available via research journals and conferences.
Conditions
- Liver Cancer
- Hepatocellular Carcinoma
- Liver Metastasis Colon Cancer
Interventions
- PROCEDURE
-
Standard Liver Surgery
Standard liver surgery using naked eye examination +/- palpation and intra-operative ultrasound scan (IOUS) examination to identify and remove liver tumours
- DIAGNOSTIC_TEST
-
Indocyanine Fluorescent Image Guided Surgery (I-FIGS)
Use of I-FIGS in accurate identification of tumours and their margins
Sponsors & Collaborators
-
University Hospital Plymouth NHS Trust
lead OTHER
Principal Investigators
-
Somaiah Aroori · University Hospitals Plymouth NHS Trust
-
Rahi Karmarkar · University Hospitals Plymouth NHS Trust
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-11-23
- Primary Completion
- 2024-05-30
- Completion
- 2024-05-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.
NCT04587739 ·Status: RECRUITING ·Phase: PHASE1
-
Hepatocarcinoma Recurrence on the Liver Study - Part2
NCT04053231 ·Status: NOT_YET_RECRUITING
-
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
NCT02762721 ·Status: COMPLETED
-
Indocyanine Green-guided Lymphadenectomy in Laparoscopic Total Mesorectal Excision for Low Rectal Cancer After Neoadjuvant Chemoradiotherapy
NCT05873621 ·Status: UNKNOWN ·Phase: NA
-
Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy
NCT07290764 ·Status: ENROLLING_BY_INVITATION
-
Utility of Intra-operative Image Guidance System for Missing Metastases
NCT02806037 ·Status: COMPLETED
-
Intra Artherial Therapies in Treatment of Primary Liver Diseases: an Observational Study
NCT06774690 ·Status: RECRUITING
-
Patient Outcomes After Hepatic Artery Infusion Pump Placement
NCT05468593 ·Status: COMPLETED
-
A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections
NCT01749332 ·Status: COMPLETED ·Phase: NA
-
Feasibility Study of Neoadjuvant Chemotherapy Modified FOLFOX6 for Resectable Liver Metastases of Colorectal Cancers
NCT00594529 ·Status: UNKNOWN ·Phase: PHASE2
-
Resection for Multiple Hepatocellular Carcinomas (HCC)
NCT01387061 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Effectiveness of Intraoperative Frozen Section on the Treatment of Suspected Gallbladder Cancer
NCT06189664 ·Status: COMPLETED
-
Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis
NCT01565811 ·Status: COMPLETED
-
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
NCT06753136 ·Status: RECRUITING ·Phase: NA
-
Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function
NCT06245785 ·Status: COMPLETED
-
A Reversal in the Vascularity of Metastatic Liver Tumors From Colorectal Cancer After the Cessation of Anti-VEGF Therapy
NCT01591109 ·Status: COMPLETED
-
Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma
NCT02613156 ·Status: COMPLETED
-
Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma
NCT02616926 ·Status: UNKNOWN ·Phase: NA
-
Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy
NCT06247293 ·Status: UNKNOWN
-
CE-IOUS for Patients With Pancreatic Cancer Undergoing Surgery: A Prospective, Proof-of-concept Trial
NCT04683497 ·Status: UNKNOWN ·Phase: NA
-
Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research
NCT06559761 ·Status: RECRUITING
-
Simultaneous Versus Staged Resection for Initially Resectable Synchronous Rectal Cancer Liver-limited Metastasis
NCT00677586 ·Status: COMPLETED ·Phase: NA
-
Circulating Tumor Cells in mCRC for Liver Resection
NCT03295591 ·Status: UNKNOWN
-
The Inflammatory Response to Stress and Angiogenesis in Liver Resection
NCT03131778 ·Status: COMPLETED ·Phase: NA
-
Imjudo & Imfinzi PMS
NCT06544629 ·Status: RECRUITING